Drug-induced liver injury (DILI) is an important cause of morbidity and mortality. DILI can even cause acute liver failure and the need for liver transplantation. Identifying DILI may be particularly difficult because it is actually an exclusion diagnosis and individuals are usually exposed to several drugs during a lifetime. Causality assessment methods are needed for objective diagnosis. The most common methods are; updated Roussel Uclaf causality assessment method (RUCAM), Narenjo adverse drug reaction probability scale and Maria and Victorino (M&V) causality assessment scale. Phenprobamate is a widely used muscle relaxant. Herein we report a rare case of repeated DILI caused by phenprobamate and review the objective diagnostic process for hepatotoxicities. Physicians should be aware of the potential adverse effects of this drug, including hepatotoxicity.
muscle antibody (ASMA), anti-liver kidney microsomal antibody (anti-LKM), antimitochondrial antibody (AMA), immunoglobulin G/ G4; genetic diseases as Wilson, Hemochromatosis, α-1 antitrypsin deficiency excluded. Thereafter; we monitored the patient to ensure liver tests normalize. Within one month of withdrawal, laboratory results were significantly normalized. dIscussIon DILI can develop following the use of many drugs. A high index of suspicion is often necessary to expeditiously establish the diagnosis. It depends on obtaining a careful drug use history and ruling out other potential causes of liver injury. 2, 3 There are no specific serum biomarkers or characteristic histologic features that reliably identify a drug as the cause of hepatic injury. [1] [2] [3] Causality assessment methods should be used for the correct diagnosis. 2, 3 As the most common methods, our patients' score of updated RUCAM were 9 (Table 2) , Narenjo adverse drug reaction probability scale was 8 and M&V causality assessment scale were 12, suggesting a likely causal relationship between phenprobamate and toxicity. [4] [5] [6] In the literature, phenprobamate toxicity has revealed itself with neurologic and psychiatric symptoms and treated by hemoperfusion and plasmapheresis. 7, 8 In Emet et al. study, their case of phenprobamate overdose (20 tablets of phenprobamate 400 mg, total dose: 8 g) was presented with various muscular and neurological symptoms. 7 The patient had received gastric lavage, activated charcoal, and hemodialysis. After a poor symptomatic recovery, she also had undergone plasmapheresis which revealed complete resolution of symptoms. During her follow-up, she also had transient hyperbilirubinemia and alkaline phosphatase elevation. Tasdemir et al. case was a 16 years old male adolescent presented with drowsiness and confusion which had 37 tablets (14.8 g) of phenprobamate with other drugs. 8 The highest dose was of phenprobamate. By early haemoperfusion and supportive care; the patient had recovered completely. Our patient had a cumulative toxic dose of phenprobamate rather than acute ingestion and was presented with mixed (cholestatic and liver) type DILI. 9 Serum levels of phenprobamate could not be determined but fortunately, our patient had also recovered by supportive care. In the literature, there is no requirement of transplantation or any methods for prevention for these patients. Also, there is one case report with abuse and dependence of phenprobamate. 10 But our patient is not compatible with this context. In addition to that; Balcı Sengul et al. indicated that phenprobamate was one of the most abused drugs in prisons in Turkey. 11 In conclusion, although it is generally known that phenprobamate is a safe and effective therapeutic agent for muscle relaxation, physicians should be aware of potential adverse effects of this drug, including hepatotoxicity. Dose reductions or mainly discontinuation of the drug may be needed in such clinical circumstances. 
